Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reifenberger

Showing results (411-420 of 562) with videos related to

Pageof 57
Sort By:
Nature Communications|November 26, 2014
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFRAnne-Theres Henze, Boyan K Garvalov, Sascha Seidel, et al.
Neuro-Oncology|June 29, 2021
The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryDavid N Louis, Arie Perry, Pieter Wesseling, et al.
Cell Death Discovery|April 5, 2022
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastomaKai Voeltzke, Katerina Scharov, Cornelius Maximilian Funk, et al.
Oncogene|December 14, 2011
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitroL M Dittmann, A Danner, J Gronych, et al.
Gastroenterology|January 24, 2012
Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndromeMario Heindl, Norman Händel, Joanne Ngeow, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2007
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcomeJohan M Kros, Thierry Gorlia, Mathilde C Kouwenhoven, et al.
Cancer Research|July 18, 2008
Temozolomide preferentially depletes cancer stem cells in glioblastomaDagmar Beier, Stefanie Röhrl, Deepu R Pillai, et al.
The Lancet. Oncology|August 1, 2014
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastomaMichael Weller, Martin van den Bent, Kirsten Hopkins, et al.
Molecular Cancer Therapeutics|September 1, 2011
Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiationAnja Uhmann, Hannah Niemann, Bérénice Lammering, et al.
Cancer Cell|October 19, 2013
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaQi-Wen Fan, Christine K Cheng, W Clay Gustafson, et al.
Pageof 57

Showing results (411-420 of 562) with videos related to

Sort By:
Pageof 57
Nature Communications|November 26, 2014
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFRAnne-Theres Henze, Boyan K Garvalov, Sascha Seidel, et al.
Neuro-Oncology|June 29, 2021
The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryDavid N Louis, Arie Perry, Pieter Wesseling, et al.
Cell Death Discovery|April 5, 2022
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastomaKai Voeltzke, Katerina Scharov, Cornelius Maximilian Funk, et al.
Oncogene|December 14, 2011
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitroL M Dittmann, A Danner, J Gronych, et al.
Gastroenterology|January 24, 2012
Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndromeMario Heindl, Norman Händel, Joanne Ngeow, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2007
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcomeJohan M Kros, Thierry Gorlia, Mathilde C Kouwenhoven, et al.
Cancer Research|July 18, 2008
Temozolomide preferentially depletes cancer stem cells in glioblastomaDagmar Beier, Stefanie Röhrl, Deepu R Pillai, et al.
The Lancet. Oncology|August 1, 2014
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastomaMichael Weller, Martin van den Bent, Kirsten Hopkins, et al.
Molecular Cancer Therapeutics|September 1, 2011
Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiationAnja Uhmann, Hannah Niemann, Bérénice Lammering, et al.
Cancer Cell|October 19, 2013
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastomaQi-Wen Fan, Christine K Cheng, W Clay Gustafson, et al.
Pageof 57